StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Repatha (evolocumab by Quarter

Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Rest of World (ROW) product sales ($M) ($M)

QuarterlyAnnual

Amgen Repatha (evolocumab: $443M in Q2 2026, up 32.2% from a year earlier. That is the highest of the 32 quarters on record here.

Latest, Q2 2026
443
Period ended Jun 30, 2026
Change on a year earlier
+32.2%
335 in Q2 2025
History
32 quarters
Since Q3 2018
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRepatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Rest of World (ROW) product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026443+32.2%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026411+31.3%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025353+21.3%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025352+23.1%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025335+27.9%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025313+28.3%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024291+34.7%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024286+28.3%Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 2024262+23.6%Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 2024244+27.7%Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 2023216+16.1%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 2023223+33.5%Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 2023212+24.0%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 2023191+16.5%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 2022186+35.8%Form 10-K (filed 2025-02-14) ↗
Q3 2022Sep 30, 2022167+25.6%Form 10-Q (filed 2023-10-31) ↗

Cite this data

StockData. (2026). Amgen Repatha (evolocumab ($M), quarterly Q3 2018–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-repatha-row

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.